Study study type PathologyT1T0Patientssample sizesROB Results

endometrial cancer endometrial cancer

versus placebo plus SoC
pembrolizumab plus SoC
NRG-GY018_pMMR, 2023
  NCT03914612
RCTendometrial cancerpembrolizumabplaceboMeasurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer. The patients were stratified into two cohorts according to whether they had mismatch repair–deficient (dMMR) or mismatch repair–proficient (pMMR) disease295 / 296low
conclusif
  • demonstrated 46 % decrease in progression or deaths (PFS) (PE)
press realease 03/2024 : OS 0.79 [0.53; 1.17]not indexed in the results due to lack of information on the timepoint for this analysis
NRG-GY018_dMMR, 2023
  NCT03914612
RCTendometrial cancerpembrolizumabplaceboMeasurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer. The patients were stratified into two cohorts according to whether they had mismatch repair–deficient (dMMR) or mismatch repair–proficient (pMMR) disease112 / 113low
conclusif
  • demonstrated 70 % decrease in progression or deaths (PFS) (PE)
press realease 03/2024 : OS 0.55 [0.25; 1.19] not indexed in the results due to lack of information on the timepoint for this analysis
versus Standard of Care (SoC)
pembrolizumab plus lenvatinib
LEAP-001/ENGOT-en9, 2024
  NCT03884101
RCTendometrial cancerpembrolizumab plus levitinibcarboplatine plus paclitaxelFirst-line Treatment of Advanced or Recurrent Endometrial Carcinoma-/-NA
inconclusive
  • inconclusive 7 % decrease in deaths (OS) (PE)
  • inconclusive 9 % decrease in progression or deaths (PFS) (PE)
KEYNOTE-775, 2023
  NCT03517449
RCTendometrial cancerpembrolizumab plus lenvatinibPaclitaxel or DoxorubicinParticipants With Advanced recurrent or metastatic Endometrial Cancer. Eligible women had disease progression after the receipt of one previous platinum-based chemotherapy regimen411 / 416some concern
conclusif
  • suggested 35 % decrease in deaths (OS) (PE)
  • demonstrated 44 % decrease in progression or deaths (PFS) (PE)
  • suggested 44 % decrease in PFS (extension)